Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Fitness to drive and cannabis: validation of two blood THCCOOH thresholds to distinguish occasional users from heavy smokers.

Fabritius M, Augsburger M, Chtioui H, Favrat B, Giroud C.

Forensic Sci Int. 2014 Sep;242:1-8. doi: 10.1016/j.forsciint.2014.05.014. Epub 2014 Jun 4.

PMID:
24999608
2.

THCCOOH concentrations in whole blood: are they useful in discriminating occasional from heavy smokers?

Fabritius M, Favrat B, Chtioui H, Battistella G, Annoni JM, Appenzeller M, Dao K, Fornari E, Lauer E, Mall JF, Maeder P, Mangin P, Staub C, Giroud C.

Drug Test Anal. 2014 Jan-Feb;6(1-2):155-63. doi: 10.1002/dta.1581. Epub 2013 Oct 31.

PMID:
24173827
3.

Assessing cannabis consumption frequency: Is the combined use of free and glucuronidated THCCOOH blood levels of diagnostic utility?

Hädener M, Martin Fabritius M, König S, Giroud C, Weinmann W.

Drug Test Anal. 2017 Jul;9(7):1043-1051. doi: 10.1002/dta.2114. Epub 2016 Nov 14.

4.

Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.

Milman G, Bergamaschi MM, Lee D, Mendu DR, Barnes AJ, Vandrey R, Huestis MA.

Ther Drug Monit. 2014 Apr;36(2):218-24. doi: 10.1097/FTD.0b013e3182a5c446.

5.

Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.

Karschner EL, Swortwood MJ, Hirvonen J, Goodwin RS, Bosker WM, Ramaekers JG, Huestis MA.

Drug Test Anal. 2016 Jul;8(7):682-9. doi: 10.1002/dta.1825. Epub 2015 Jun 11.

6.

Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint.

Fabritius M, Chtioui H, Battistella G, Annoni JM, Dao K, Favrat B, Fornari E, Lauer E, Maeder P, Giroud C.

Anal Bioanal Chem. 2013 Dec;405(30):9791-803. doi: 10.1007/s00216-013-7412-1. Epub 2013 Nov 8.

PMID:
24202191
7.

Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence.

Lee D, Milman G, Barnes AJ, Goodwin RS, Hirvonen J, Huestis MA.

Clin Chem. 2011 Aug;57(8):1127-36. doi: 10.1373/clinchem.2011.164822. Epub 2011 Jun 15.

8.

Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis.

Desrosiers NA, Himes SK, Scheidweiler KB, Concheiro-Guisan M, Gorelick DA, Huestis MA.

Clin Chem. 2014 Apr;60(4):631-43. doi: 10.1373/clinchem.2013.216507. Epub 2014 Feb 21.

9.

Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws.

Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RH, Huestis MA.

Clin Chem. 2013 Mar;59(3):519-26. doi: 10.1373/clinchem.2012.195503.

10.

[Time profile of serum THC levels in occasional and chronic marihuana smokers after acute drog use - implication for drivind motor vehicles].

Balíková M, Hložek T, Páleníček T, Tylš F, Viktorinová M, Melicher T, Androvičová R, Tomíček P, Roman M, Horáček J.

Soud Lek. 2014;59(1):2-6. Czech.

PMID:
24625019
11.

Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.

Schwope DM, Karschner EL, Gorelick DA, Huestis MA.

Clin Chem. 2011 Oct;57(10):1406-14. doi: 10.1373/clinchem.2011.171777. Epub 2011 Aug 11.

12.

Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.

Karschner EL, Schwilke EW, Lowe RH, Darwin WD, Herning RI, Cadet JL, Huestis MA.

J Anal Toxicol. 2009 Oct;33(8):469-77.

13.

Cannabis use: a perspective in relation to the proposed UK drug-driving legislation.

Wolff K, Johnston A.

Drug Test Anal. 2014 Jan-Feb;6(1-2):143-54. doi: 10.1002/dta.1588. Epub 2013 Dec 11. Review.

PMID:
24327278
14.

Development of a rapid column-switching LC-MS/MS method for the quantification of THCCOOH and THCCOOH-glucuronide in whole blood for assessing cannabis consumption frequency.

Hädener M, Weinmann W, Schürch S, König S.

Anal Bioanal Chem. 2016 Mar;408(7):1953-62. doi: 10.1007/s00216-016-9311-8. Epub 2016 Jan 18.

PMID:
26781107
15.

Urinary cannabinoid disposition in occasional and frequent smokers: is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers?

Desrosiers NA, Lee D, Concheiro-Guisan M, Scheidweiler KB, Gorelick DA, Huestis MA.

Clin Chem. 2014 Feb;60(2):361-72. doi: 10.1373/clinchem.2013.214106. Epub 2013 Nov 1.

16.

Effect of Blood Collection Time on Measured Δ9-Tetrahydrocannabinol Concentrations: Implications for Driving Interpretation and Drug Policy.

Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney GR, Huestis MA.

Clin Chem. 2016 Feb;62(2):367-77. doi: 10.1373/clinchem.2015.248492.

17.
18.

Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers.

Anizan S, Milman G, Desrosiers N, Barnes AJ, Gorelick DA, Huestis MA.

Anal Bioanal Chem. 2013 Oct;405(26):8451-61. doi: 10.1007/s00216-013-7291-5. Epub 2013 Aug 17.

19.
20.

Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.

Lowe RH, Abraham TT, Darwin WD, Herning R, Cadet JL, Huestis MA.

Drug Alcohol Depend. 2009 Nov 1;105(1-2):24-32. doi: 10.1016/j.drugalcdep.2009.05.027. Epub 2009 Jul 23.

Supplemental Content

Support Center